This article was originally published in Pharmaceutical Approvals Monthly
Receives additional six-month marketing exclusivity for all formulations of the product based on pediatric studies. Loratadine's compound patent is set to expire in June 2002. The pediatric studies support two sNDAs for the syrup formulation of loratadine. The first was filed in November 1999 for treatment of seasonal allergic rhinitis in children two to five years old. The second sNDA, filed in June 2000, would add safety information to labeling for children six months to two years old. Claritin Syrup is currently indicated for use in children 6 and olde
You may also be interested in...
Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.
Broader than initially reported, Merck & Co.’s agreement with BARDA extends beyond J&J’s recently authorized vaccine to other COVID-19 vaccines and therapeutics as needed.